NovaBay® Pharmaceuticals, Inc. has received 510(k) clearance from the Food and Drug Administration (FDA) to market NeutroPhase® Skin and Wound Cleanser under widened indications including the moistening and debriding of graft and donor sites.
The new indications will give surgeons greater flexibility in the management of graft and donor-site surgical procedures.
The FDA also cleared NeutroPhase to be administered via a spray pump.
NovaBay is currently seeking appropriate potential partners to out-license rights to NeutroPhase in North America and Europe. For more information, visit www.NeutroPhase.com.